GET THE APP

Assessment of the gastropanel test as a non-invasive diagnosis of atrophic gastritis
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Assessment of the gastropanel test as a non-invasive diagnosis of atrophic gastritis


3rd World Congress on Cancer Science & Therapy

October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

Alonge Ivo Ebule

University of Yaounde I, Cameroon

Accepted Abstracts: J Cancer Sci Ther

Abstract :

G astric colonization by Helicobacter pylori increases the risk of atrophic gastritis and gastric cancer. Serum levels of pepsinogen I and gastrin-17 which are respectively biomarkers of corpus and antrum mucosal activity are well known parameters of atrophic gastritis. We examined the diagnostic efficacy of GastroPanel serological kit (pepsinogen I& II, gastrin-17 and H. pylori IgG), in diagnosing and scoring atrophic gastritis. Dyspepsia patients undergoing gastroscopy with biopsy were recruited prospectively on voluntary basis at the Yaounde Central and University Teaching Hospitals, from March to July 2011. The degree of atrophy was classified according to levels of serum pepsinogen I &II, gastrin-17 and H.pylori IgG and compared with histological profiles. 86 volunteers aged 21 to 83, mean ± C.I. (46.4±3.3) were enrolled. The prevalence of gastritis was statistically similar between GastroPanel test and histology (89.5% versus 83.7%: p>0.20). However, the GastroPanel diagnosed more atrophic gastritis than histology (17.4% versus 7.0%: p<0.01), especially at antrum of stomach with H. pylori infection. For the scoring of atrophy, the accuracy (69.77%), sensitivity (85.70%) and specificity (88.60%) were calculated. The prevalence of H. pylori-infection did not differ significantly between serological and histological methods (84.9% versus 81.4%, p>0.05). These results suggest that diagnosis of atrophic gastritis and H. pylori infection obtained with an optional serological method, GastroPanel is in strong agreement with biopsy findings, and thus can be a useful non-endoscopic assessment of stomach mucosal atrophy in patients with dyspepsia.

Biography :

Alonge Ivo Ebule has completed his M.Sc. in Medical Immunology at the age of 30 from University of Yaounde 1 in 2012 and a Bachelor of Medical Laboratory Sciences from the University of Buea in 2007. Since 2006, he has assumed a leadership role in gastric research. He is a consultant with the Ministry of Public Health and several non-governmental organizations. He has published 03 papers in gastric diseases and has participated actively in other research areas including immunopathology of malaria and onchocerciasis with the use of cytokines along the Sanaga valley of Cameroon.

Email: [email protected]

tempobet

tempobet giriş

tempobet giriş

süperbetin

tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward